Skip to Content


Clinical Trials Details

Type 2 Diabetes

Seeking subjects with Type 2 diabetes Mellitus




LILLY VIVID: Safety and efficacy of Human Regular U-500 Insulin administered by continuous subcutaneous insul infusion versus multiple daily injections in subjects with Type 2 Diabetes Mellitus: A randomized, open-label, parallel Clinical trial


Billings Clinic Research is conducting a research study to evaluate the safety and effectiveness of an approved, injectable form of insulin using an insulin pump.  The use of the insulin in the study device is investigational.


Qualified participants will receive the following at no cost:

  • All study related care
  • Study Medication

This study is being done to evaluate the efficacy and safety of U-500R given by the OmniPod U-500 system (insulin pump) compared to U-500R given by multiple daily injections (MDI) in patients with type 2 diabetes mellitus. "Investigational" means use of the drug in the new device being tested has not been approved together for routine clinical use or for the use described in this study by the United States Food and Drug Administration (FDA). However, the FDA has allowed the use of this drug within this new device for research. OmniPod Insulin Pump is not commercially available with internal software appropriate for U-500R insulin dosage in U-500R insulin units. U-500R insulin administered subcutaneously by MDI is commercially available

IRB Protocol Number
Principal Investigator(s)
Christopher Sorli, MD
Jeanne Ortiz, MD
Eli Lilly Inc
Recruitment Hotline at 406-657-4111


  • Billings Clinic North 30th Building
    1045 North 30th St
    Billings, MT 59101
    Main: 406-238-2500